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Abstract: Recently, I put forth the hypothesis that the signaling molecule, norepinephrine (NE), 
is an etiological factor in a number of types of cancer. In this brief commentary, I summarize 
evidence that NE plays a role in cancer and describe details involved in testing the hypothesis 
in humans through epidemiological investigation of existing medical records of persons who 
have taken pharmaceutical drugs that affect NE. If NE plays an etiological role in cancers of 
a number of organs, then taking a single pharmaceutical drug (such as clonidine, prazosin, or 
propranolol) that weakens NE signaling systemically, may simultaneously prevent or treat many 
different types of cancer, and this may represent a breakthrough in pharmaceutical prevention 
and possibly treatment of cancer.
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In a recent paper,1 I put forth the hypothesis that the signaling molecule, norepinephrine 
(NE), is an etiological factor in a number of types of cancer. This is an unusual 
hypothesis because NE is a neurotransmitter in the brain and sympathetic nervous 
system. Intracellular molecular pathways and hormones have been studied extensively 
in cancer research, but to my knowledge neurotransmitter signaling molecules have 
hardly been studied at all.
In this brief commentary, I summarize evidence that NE plays a role in cancer and 
describe details involved in testing the hypothesis in humans through epidemiological 
investigation of existing medical records of persons who have taken pharmaceutical 
drugs that affect NE. If NE plays an etiological role in cancers of a number of organs, 
then taking a single pharmaceutical drug that weakens NE signaling systemically may 
simultaneously prevent or treat many different types of cancer, and this may represent 
a breakthrough in pharmaceutical prevention and possibly treatment of cancer.
NE plays various signaling roles in many organs in addition to the brain. It is not 
a new concept that NE is involved in cancer as a group of Russian scientists and a 
group of Japanese scientists were already investigating the phenomenon in rodents 
several decades ago.2,3 I put forth1 evidence that NE is an etiological factor in cancer 
related to both human and animal studies. I also pointed out that NE has direct access 
to many of the organs in which cancer can develop.
The most important point of my previous paper1 is that use of existing pharmaceutical 
drugs that either lower the level of NE (such as clonidine) or block NE receptors (such 
as propranolol and prazosin) may lower the probability of an individual developing 
cancer (and possibly treat existing cancers). Since the above three drugs, as well as Clinical Epidemiology 2010:2 
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plenty of similar drugs, have been on the market in the United 
States for decades, retrospective epidemiological analysis of 
the medical records of thousands (if not millions) of people 
who have taken these drugs is immediately feasible. This 
will be discussed below.
Why might NE affect cancer in the first place? Since NE 
is a sympathetic nervous system “stress hormone” that helps 
mediate the body’s “fight or flight” response to environmen-
tal stressors, perhaps having (largely genetic) elevated NE 
tone keeps the body in a state of diminished maintenance or 
homeostatic processing, resulting in an increased probability 
of developing cancer. A related point is that boosting another 
signaling molecule, acetylcholine, with pharmaceutical drugs 
such as donepezil might help prevent cancer, since acetylcho-
line helps mediate the body’s homeostatic, parasympathetic 
“rest and digest” functioning. In addition, the stress hormone 
epinephrine (adrenaline) may also play a role in cancer, as 
it activates the same endogenous adrenoceptors as NE, but 
there is less evidence that epinephrine plays such a role. 
It would also be informative to investigate whether the stress 
hormone, cortisol, affects cancer risk.
In testing the NE/cancer hypothesis epidemiologically, 
the basic idea is that pharmaceutical drugs that enhance NE 
signaling should increase the risk of cancer, whereas drugs 
that reduce NE signaling should decrease the risk of cancer. 
This latter possibility may seem counterintuitive, since most 
epidemiological studies to my knowledge have found that 
pharmaceutical drugs increase rather than decrease cancer 
risk. Regarding drugs that increase NE signaling: tricyclic 
antidepressants boost the level of NE (possibly systemically) 
and have already been associated with increased cancer risk, 
although this issue is controversial.4–7 Studying the effects of 
tricyclics on cancer risk, or two newer NE-boosting drugs, 
reboxetine and atomoxetine, is an area of research that would 
benefit significantly from greater investigation.
The most important avenue of epidemiological investiga-
tion into the NE/cancer hypothesis may be to study whether 
pharmaceutical drugs that weaken NE signaling lower 
cancer risk. These drugs comprise three main categories: 
alpha1 antagonists (such as prazosin), beta blockers (such as 
propranolol), and alpha2 agonists (such as clonidine). Drugs 
in the first two categories block postsynaptic NE signaling, 
whereas clonidine may principally lower the level of NE 
both centrally and peripherally, thereby decreasing NE trans-
mission. All of these drugs have been on the market in the 
United States for decades and thousands of people have taken 
them and continue to take them, increasing the feasibility of 
epidemiological investigation. These drugs are typically used 
to treat hypertension or cardiac disorders. An important point 
is that when epidemiologically testing the effect of these drugs 
on cancer risk, it would be informative to compare persons on 
these drugs with persons who have the same disorder (such 
as hypertension) but are taking a drug that does not affect NE 
(such as a calcium-channel blocker) for the same condition. 
Comparison of cancer rates in persons on NE drugs with 
persons taking no pharmaceutical drugs at all would also be 
valuable. It would also be useful to not only test the effects 
of NE-weakening drugs on risk of a particular type of cancer, 
but also whether these drugs reduce cancer risk for a number 
of different cancers simultaneously.8 In addition, if there are 
enough data, it would be informative to test whether the treat-
ment outcome of persons with existing cancers is affected 
by simultaneous use of NE-altering drugs.
A recent study indicates that exposure to doxazosin and 
terazosin, which are NE alpha1 receptor-blocking drugs, 
reduces the risk of prostate cancer,9 as does exposure to beta 
blockers.10 Exposure to beta blockers may produce a general 
decrease in cancer risk,8 which already provides evidence 
for a general effect of NE on cancer risk.
Acute boosting of NE probably has little or no effect on 
cancer risk, since the body’s own fight-or-flight response 
releases large amounts of NE when activated, and people 
don’t develop cancer each time this occurs (although repeated 
stressors may increase risk). Therefore, critical care patients 
who receive exogenous NE to maintain a stable hemodynamic 
status should not be at higher risk for developing cancer. 
I hypothesize that it is chronically elevated NE, or chronic 
use of NE-altering drugs, that significantly affects cancer risk. 
If so, pharmacoepidemiological studies that would examine 
the NE/cancer hypothesis should focus on individuals who 
are exposed to NE-altering drugs (or psychological stress) 
for months or years. Since drugs such as clonidine, pro-
pranolol, and prazosin are often taken for many years due to 
treatment of chronic hypertension or cardiac disorders, this 
increases the feasibility of epidemiological investigation of 
the hypothesis.
Which types of cancer might NE affect? One possibility 
is that NE affects cancer in every organ that it innervates. 
This includes the eye, brain, breast, spinal cord, heart, lung, 
blood, blood vessels, kidney, liver, stomach, pancreas, intes-
tines, uterus, prostate gland, skin, and skeletal muscles.1 
However, a counterpoint to the NE/cancer hypothesis is that 
both the heart and blood vessels, which have a high density 
of adrenoceptors, rarely develop tumors. Vascular malforma-
tions may be related more to growth factor phenomena than to 
adrenergic stimulation. On the other hand, a combination of Clinical Epidemiology 2010:2
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effects by growth factors and adrenergic stimulation, perhaps 
at a cellular level following second messenger signaling, may 
well be a promising theory for carcinogenesis.
Even if chronic use of antidepressants or adrenergic 
receptor blocker medications does indeed have an effect 
on cancer risk, this does not confirm an etiological role for 
endogenous NE in cancer. It may merely indicate an asso-
ciation. Perhaps NE is a factor in the pathogenesis, and is a 
mediator somewhere in the much more complex process of 
developing cancer. In this scenario, use of NE-altering drugs 
may nonetheless be a means for lowering the probability of 
developing some types of cancer.
I would encourage epidemiologists reading this to 
strongly consider investigating the potential link between 
NE and cancer, as it could lead to immediate improvement in 
the pharmacological prevention and treatment of many types 
of cancer. Feel free to contact me for discussion.
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